Home / Anti-infectives / Emtricitabine
ATC J05AF09 · Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
Emtricitabine shortage
As of 2 Nov 2026, Emtricitabine has a reported shortage in 2 of the 16 countries we track (United States, Australia), covering 3 products from 1 company.
Countries2/16
Products3packs or presentations
Companies11 listed
Short since15 May 20266 months ago
Earliest return18 Dec 2026company estimate
Main reasonNot stated
United States2 products shortCanadaNo reported shortageGermanyNo reported shortageFranceNo reported shortageItalyNo reported shortageSpainNo reported shortageIrelandNo reported shortageAustriaNo reported shortageBelgiumNo reported shortageSwitzerlandNo reported shortageCzechiaNo reported shortageNorwayNo reported shortageSwedenNo reported shortageJapanNo reported shortageNew ZealandNo reported shortageAustralia1 product short
Timeline
United StatesAustralia
Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.
Which companies are short
products short, all countriesListed: Gilead GILD · Nasdaq
Compared with similar medicines
ATC group J05AF · Nucleoside and Nucleotide Reverse Transcriptase InhibitorsAffected products
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Emtriva, Capsule, 200 mg (NDC 61958-0601-1) discontinuation | Gilead Sciences, Inc. | 17 Jun 2026 | not given | Not stated |
| US | Emtriva, Oral Solution, 10 mg/1 mL (NDC 61958-0602-1) discontinuation | Gilead Sciences, Inc. | 17 Jun 2026 | not given | Not stated |
| AU | Tenofovir/Emtricitabine 300/200 ARX tenofovir disoproxil fumarate 300 mg emtricitabine 200 mg tablet blister pack discontinuation | 15 May 2026 | 18 Dec 2026 | Not stated |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.